
Novavax rose 53.2% from $7.11 to $10.89, ahead of the S&P 500's +10.5%. Its worst day was Oct 16 (−12.2%), and its low came Nov 20 at $6.22.
Nov 10, 2025 – Nov 9, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Novavax closed at its lowest level of the year, 12.5% below where the year started.
−1.9% · S&P 500 −1.5%
Novavax Inc (NASDAQ:NVAX) shares are trading higher.
+11.9% · S&P 500 −0.2%
Story events cover the past 12 months · Times ET
Novavax shares rose 20.7%, while the S&P 500 rose 1.2%.
+20.7%, the year's best day · S&P 500 +1.2%
EPS of $0.11 beat the $-0.56 estimate on $147.1M revenue (est. $85.5M); FY revenue guidance of $230.0M–$270.0M against the $402.0M consensus.
+17.4% · S&P 500 −0.6%
EPS of $-0.06 beat the $-0.23 estimate on $139.5M revenue (est. $76.9M); FY revenue guidance of $230.0M–$270.0M against the $387.8M consensus.
+15.6% · S&P 500 +1.4%
Novavax shares rose 13.6%, while the S&P 500 rose 0.7%.
+13.6% · S&P 500 +0.7%
EPS of $-0.32 beat the $-0.37 estimate on $56.7M revenue (est. $51.7M); FY revenue guidance of $235.0M–$275.0M against the $402.3M consensus.
+0.5% · S&P 500 −0.2%
Novavax shares rose 20.1%, while the S&P 500 rose 0.7%.
+20.1%, on 29M shares, the year's heaviest volume · S&P 500 +0.7%
Novavax closed at its highest level of the year, 80.3% above where the year started.
+1.3% · S&P 500 0.0%
EPS of $-0.19 beat the $-0.35 estimate on $68.3M revenue (est. $50.5M); FY revenue guidance of $385.0M–$415.0M against the $382.6M consensus.
−8.2% · S&P 500 −4.4%
Where it ended: a close of $10.89 on Nov 9, 2026. Up next: Q4 2026 earnings on Feb 25, 2027 (EPS est. $0.50, revenue est. $203.1M).
Nothing in the past 12 months.
All NVAX dividend historyReplay the year: the line draws itself and stops at each of the 10 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for NVAX and SPY from Benzinga historical bars. Not investment advice.